Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Galmed Pharmaceuticals Ltd
GLMD | US
0.47
USD-0.23
-32.57%
GLMD | US
Loading StockChartView...
About Galmed Pharmaceuticals Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
08/06/2026
Close
0.47
Open
0.59
High
0.64
Low
0.42
Galmed Pharmaceuticals Ltd. a biopharmaceutical company focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol an oral therapy which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition it engages in the development of Amilo-5MER a 5 amino acid synthetic peptide methionine threonine alanine aspartic acid and valine. It has a license agreement with Samil Pharma. Co. Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv Israel.
View LessGLMD | US
Risk
151.5
Sharpe
-0.79
Luna's Score
33/100
Recommendation
Sell
Luna says (GLMD | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
201.6%1 month
151.5%3 months
117.2%6 months
100.9%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.44
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
0.32
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-6.14M
MarketCap
707.23K
MarketCap(USD)
707.23K
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-52.67
Short ratio
-
Short perc.
2.30
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.38
Range1M
0.38
Range3M
0.85
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
17.77
Price X volume
10.10M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.32 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.44 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 117.20 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 707.23K | 3.66B | Emerging |
